RxDoctor Payments DataLook up a doctor →

Bonnie Levin, DO

Family Medicine · Cherry Hill, NJNPI 1841371028

Payments from drug & device makers

$15,435in general payments, 2019–2025

Across 679 payments — averaging $22.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AstraZeneca$2K
  • Amarin Pharma, Inc.$2K
  • Amgen$1K
  • AbbVie$900
  • Bayer$730
  • plus $5K from 34 others

What the payments were for

  • Food & beverage$15,389100%
  • Education$460%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,435 in reported general payments places this provider in the 95th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$104,995
Medicare patients
116
Services billed
1,116

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide86$132,918
FarxigaDapagliflozin Propanediol89$81,733
MounjaroTirzepatide27$48,807
JardianceEmpagliflozin27$39,321
MyrbetriqMirabegron35$33,653
EliquisApixaban26$26,425
JanuviaSitagliptin Phosphate33$26,326
Repatha SureclickEvolocumab15$18,705
VascepaIcosapent Ethyl13$9,553
Breo ElliptaFluticasone/Vilanterol16$7,891
Spiriva HandihalerTiotropium Bromide11$5,630
Tresiba Flextouch U-100Insulin Degludec12$3,993
Atorvastatin Calcium233$2,617
Levothyroxine Sodium125$2,104
Metoprolol Succinate98$1,771

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$3,075$132,91886 claims
AstraZenecaFarxiga$2,293$81,73389 claims
Lilly USA, LLCMounjaro$521$48,80727 claims
Boehringer IngelheimJardiance$122$39,32127 claims
Astellas Pharma US IncMyrbetriq$177$33,65335 claims
PfizerEliquis, Paxlovid$98$27,85446 claims
MerckJanuvia$126$26,32633 claims
GSKBreo Ellipta$232$7,89116 claims
AbbVieSynthroid$900$1,27120 claims
ANI Pharmaceuticals, Inc.Valsartan$174$45714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Cherry Hill

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →